Trial Profile

Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 22 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tumour infiltrating lymphocytes (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
Indications Adenocarcinoma; Carcinoma; Colorectal cancer; Osteosarcoma; Ovarian cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Sarcoma
Focus Therapeutic Use

Most Recent Events

26 Aug 2024 Status changed from active, no longer recruiting to discontinued due to lack of efficacy
08 Jan 2024 Planned End Date changed from 1 Jan 2025 to 31 Jan 2025.
08 Jan 2024 Planned primary completion date changed from 1 Jan 2024 to 31 Jan 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com